“`html
Positive
- Board appointment of Michael Raimondo on October 10, 2025
- Raimondo credited with driving over $500 million in sales contracts
- Immediate commercial focus to scale Venowave via internal sales team and reseller channels
10/10/2025 – 06:30 AM
Toronto, Ontario – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a player in advanced diagnostic and medical device technologies, revealed the appointment of Michael Raimondo, a three-decade stalwart in healthcare sales and operations, to its Board of Directors. Raimondo previously served on Therma Bright’s advisory board as of August 13, 2024.
Raimondo brings a wealth of experience in commercial leadership, particularly in the healthcare and business services industries. His expertise in sales negotiations has resulted in over $500 million in sales contracts. This appointment signals Therma Bright’s commitment to scaling commercial operations and accelerating the market penetration of its key product, Venowave.
Prior to joining Therma Bright, Raimondo held senior leadership positions at Abbott, concentrating on commercial strategy and business development. His experience at Abbott provides a valuable perspective on large-scale commercialization strategies. His transition from Abbott included advisory and executive roles across a spread of organizations.
Currently, Raimondo is the Commercial Lead for Delphine Diagnostics in New Jersey, spearheading market strategy and business expansion. He also serves as a Managing Partner at The Potentia Group, specializing in negotiations training, sales leadership development and consulting within the U.S. healthcare market. He holds a BS in physics and a minor in mathematics from Kutztown University.
“We are thrilled to have Michael join us in a strategic role as a full Board Member, where we will fully utilize his vast commercial expertise,” stated Rob Fia, CEO of Therma Bright. Fia highlighted that Raimondo’s knowledge would be instrumental in accelerating market penetration and driving sales of Venowave, Therma Bright’s flagship medical device.
Raimondo expressed his enthusiasm for joining the Board, stating, “I am pleased to be joining the Board and contributing to the significant growth potential of the Venowave platform. My primary focus will be on leveraging my commercial experience to rapidly scale the organization-specifically by designing and implementing a high-performance, results-driven internal sales team. Simultaneously, I look forward to enhancing our market reach by expanding our channels through strategic partnerships with high-value medical device resellers, ensuring Venowave reaches patients suffering from vascular issues, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC.” Addressing potential investors, his strategy appears aimed at aggressive growth and securing market share within a competitive medical device landscape.
Concurrently, Therma Bright announced the resignation of Board member Alex Saringer. The Company thanked Saringer for his service.
About Therma Bright Inc.
Therma Bright develops and partners in diagnostic and medical device technologies for consumers and medical professionals. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0).
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements relating to future sales of Venowave. These statements involve risks and uncertainties. Actual results could differ materially from those anticipated due to several factors. Therma Bright disclaims any intention or obligation to update or revise any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
FAQ
Who did Therma Bright (TBRIF) appoint to its board on October 10, 2025?
Therma Bright appointed Michael Raimondo, a 30-year healthcare commercial executive, to its Board of Directors.
What experience does Michael Raimondo bring to Therma Bright (TBRIF)?
He brings 30 years in US healthcare sales and operations, senior roles at Abbott, and is credited with over $500 million in sales contracts.
How will Michael Raimondo support Venowave commercialization for TBRIF?
He plans to design a high-performance internal sales team and expand channels through strategic medical device resellers to accelerate Venowave sales.
Did Therma Bright (TBRIF) announce any board departures on October 10, 2025?
Yes. The company announced the resignation of board member Alex Saringer.
What current roles does Michael Raimondo hold that relate to his new TBRIF board position?
He is Commercial Lead at Delphine Diagnostics (NJ) and Managing Partner at The Potentia Group, focusing on sales leadership and negotiations.
Does Michael Raimondo plan to target a specific patient population with Venowave for TBRIF?
He referenced expanding reach to patients with vascular issues, noting an audience including about 900,000 US citizens who suffer deep vein thrombosis each year per CDC figures.
